anadrol for sale

anadrol for sale ® has a pronounced antiplatelet, anti-platelet activity angioprotective and anti-inflammatory properties, has venotoniziruyuschee and improves microcirculation action activates diuretic renal function.
anadrol for sale ® has an effect on the overall condition of the body: increases physical performance, shows stress-protective activity and a moderate analgesic effect.

Indications

In the complex treatment of diseases associated with vascular disorders, such as increased platelet aggregation (thrombosis, embolism), violation of capillary permeability and microcirculation (capillary thrombosis), violation of venous circulation (varicose veins, post-thrombotic syndrome, thrombophlebitis).

Contraindications

Hypersensitivity to the drug, severe chronic liver disease, kidney and gastrointestinal tract in violation of their functions. The lack of lactase, lactose intolerance, lack of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption (due to the presence of lactose and sucrose).
We do not recommend use of the drug for children under the age of 18 years, during pregnancy and breastfeeding period due to lack of clinical safety data applications.

Dosing and Administration

anadrol for sale ® is taken orally 1 tablet 3 times a day 40 minutes after eating. The duration of treatment up to 3 weeks. Perhaps the increase in single-dose anadrol for salea ® to 2 tablets 3 times a day in case of good tolerability. The need to re-rate is determined by the doctor.

Side effect

Allergic reactions, dyspeptic disorders.

Overdose

With prolonged use anadrol for salea ® at doses higher than the recommended daily dose may increase the severity of dose-dependent side effects. Treatment is symptomatic.

Interaction with other drugs

Application anadrol for salea ® can be combined with other drugs: lipid-lowering, anti-inflammatory, pain relievers, antibiotics, anticoagulants direct and indirect action.

special instructions

Use of the drug has no effect on the capacity for road management and engage in other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Information for diabetics: one tablet contains 0.023 bread units (BU), in the maximum daily dose – 0.138 bread units (BU).

Product form:

Tablets 100 mg coated tablets.
10 tablets in blisters of PVC film and aluminum foil printing patent or paper packaging with a plastic coating.
In 30 tablets in glass lighting banks, or banks polymer, or in canisters made of polymeric materials.
every bank, every pencil case, 1, 2 or 3 blisters with instruction on use are placed in a pile of cardboard.

anadrol cycle

anadrol cycle® is a complex preparation containing vitamins of group B. It has the ability to activate key enzymes in the body and transsulfatsii remethylation methionine – methylenetetrahydrofolate and tsistation-B synthetase, thereby accelerating the exchange of methionine and a decrease in the blood concentration of homocysteine.

Hyperhomocysteinemia is an important risk factor for atherosclerosis and arterial thrombosis and myocardial infarction, ischemic cerebral stroke, diabetic angiopathy. The emergence of hyperhomocysteinemia contributes to the deficit in the body of folic acid and vitamins B6 and B12.

Normalizing the level of homocysteine in the blood against the background of complex application of these vitamins prevents the progression of atherosclerosis and thrombosis, easier for coronary heart disease, cerebrovascular disorder, diabetic angiopathy.

Indications

– In the treatment of coronary heart disease, cerebrovascular insufficiency in genesis of atherosclerosis, diabetic angiopathy in adults.

– Hyperhomocysteinemia.

Contraindications. Hypersensitivity to the drug.

Dosage and administration. Inside, 1 tablet per day regardless of the meal. The course of treatment 20-30 days.

 

Side effect:

Allergic reactions.

 

Interaction with other drugs:

Folic acid. Reduces the effect of phenytoin (requires an increase in the dose).

Analgesics (long-term therapy), anticonvulsants (including phenytoin and carbamazepine), estrogens, oral contraceptives increase the need for folic acid.

Antacids (including aluminum and magnesium preparations), colestyramine, sulfonamino (including sulfasalazine) reduce the absorption of folic acid.

Methotrexate, pyrimethamine, triamterene, trimethoprim inhibit dihydrofolate anadrol cycle reductase and reduce the effect of folic acid.

Pyridoxine hydrochloride. It enhances the effect of diuretics; It weakens the activity of levodopa.

Isonicotinyl hydrazide, penicillamine, cycloserine and estrogensoderzhaschie oral contraceptives impair the effect of pyridoxine.

Good with cardiac glycosides (pyridoxine promotes synthesis of contractile proteins in the myocardium), glutamic acid and asparkamom (hypoxia increases the resistance).

Cyanocobalamin. Aminoglycosides, salicylates, anti-epileptic drugs, colchicine, potassium supplements reduce the absorption of cyanocobalamin. Increases the risk of allergic reactions against the backdrop of thiamine.

Can not be combined with drugs that increase blood clotting.

anadrol reviews

Cephalosporin antibiotic II generation of cephamycins group for parenteral administration. The bactericidal action is due to the blocking of bacterial transpeptidase, which leads to disruption of the closing stages of the cell walls of microorganisms synthesis. It has a broad antimicrobial spectrum against both aerobic and anaerobic bacteria. The unique molecular structure tsefoksitina determines its high resistance to bacterial beta-lactamases. It is active against gram-positive aerobes – of Staphylococcus aureus and of Staphylococcus epidermidis (including producing and producing no penicillinase-producing strains), beta-hemolytic group A streptococci ( of Streptococcus pyogenes ), beta-hemolytic streptococci group In ( Streptococcus agalactiae ), Streptococcus pneumoniae ; aerobic Gram – Escherichia coli, Haemophilus influenzae, Eikenella corrodens (not beta-lactamase producing strains),K. pneumoniae, of Neisseria gonorrhoeae (including producing and producing no penicillinase strains), Morganella morganii, the Proteus mirabilis, the Proteus vulgaris, Providencia spp. (including Providencia rettgeri), Salmonella spp, Shigella spp,.. as well as clinically significant anaerobes – of Actinomyces spp,. Clostridium spp. (except Clostridium difficile), Peptococcus niger, Peptostreptococcus spp. , microaerophilic Streptococcus, Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides spp., Prevotella bivia. anadrol reviews activity against metitsillinoustoychivyh Staphylococcus spp., enterococcus, Listeria monocytogenes, Enterobacter cloacae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Mycobacterium spp., Rickettsia spp., Chlamydia spp., Mycoplasma spp., Ureaplasma spp.

Pharmacokinetics

After 5 min after bolus intravenous (i / v) administration of 1 g and 2 g anadrol reviews maximum serum concentration (Cmax) is 110 and 244 mg / l, respectively. After 4 hours after intravenous administration at a dose of 1 g serum concentrations less than 1 mg / l. Following intramuscular (i / m) administration of 1 g of anadrol reviews Cmax observed and after 20 minutes is 30 mg / liter.
It penetrates into fluids and tissues of the body: the pleural, ascites and synovial fluid; bactericidal concentrations determined in bile. The volume of distribution – 0.16 l / kg. Relationship to plasma proteins – 70-80%. Excreted in breast milk in low concentrations.
Excreted mainly by the kidneys in unchanged form (85% by glomerular filtration, 6% – tubular secretion), while in urine are high concentrations of the drug. In the form of inactive metabolites derived only 0.2-5% of the administered dose. The half-life (T ½ ) when administered intravenously is from 41 to 59 minutes, in the elderly – from 51 to 90 minutes.

Indications
Infections caused by susceptible microorganisms:

  • lower respiratory infections, including pneumonia, empyema pleura, lung abscess;
  • abdominal infections, including peritonitis, abdominal abscess;
  • infectious and inflammatory diseases of the pelvic organs, including endometritis, pelvioperitonit, salpingo;
  • Urinary tract infections (pyelitis, pyelonephritis);
  • Skin and soft tissue infections,
  • infections of bones and joints;
  • uncomplicated gonorrhea;
  • septicemia.

Prevention of postoperative infectious complications.

Contraindications:
Hypersensitivity to anadrol reviews and other cephalosporin antibiotics.

Precautions
In patients with allergic reactions to penicillin in history as possible cross-allergy between penicillins and cephalosporins; When specifying a history of ulcerative colitis; renal insufficiency.

Pregnancy and lactation
Application Anaerotsefa ® in pregnant women is possible in cases where the expected benefit to the mother outweighs the potential risk to the fetus and should be administered under the supervision of a specialist. During treatment anadrol reviews should stop breastfeeding.

Dosing and Administration
Depending on the dose and the severity of the infection, Anaerotsef ® can be administered in / in (jet or / drip) or / m.
For adults sredneterapevticheskih dosage is 1-2 g every 6-8 hours.
In uncomplicated urinary tract infections – in / m 2 to 1 g twice daily. In uncomplicated gonorrhea, including penicillinase-producing strains caused by Neisseria gonorrhoeae , administered once / m at a dose of 2 g; at the same time (or 1 hour later) is taken orally 1 g probenecid.
In severe infections in / route of administration is preferred; appoint 2 g every 4 hours or 3 g every 6 hours. The daily dose should not exceed ’12
Tsefoksitin excreted from the body mainly by the kidneys, so patients with kidney failure require correction of the mode of administration depending on creatinine clearance values (see. table ):

Dosing Anaerotsefa ® in patients with renal insufficiency

Creatinine clearance
ml / min
Dose, g The interval between
doses
30-50 1-2 8-12 hours
10-29 1-2 12-24 hours
5-9 0,5-1 12-24 hours
<5 0,5-1 24-48 h

Patients, located on hemodialysis, it is recommended after each hemodialysis additionally administered 1-2 g Anaerotsefa ® . Children older than 1 month. Anaerotsef ® is administered at the rate of 30-40 mg / kg every 6-8 hours (maximum daily dose should not exceed 12 g). In mild and moderate infections may intramuscular injection, in severe infections preferably by intravenous injection or infusion of the drug. Children up to 3 months. Anaerotsef ® is administered only intravenously. Newborn and first week of life in preterm infants weighing more than 1500 g is administered intravenously at a dose of 30-40 mg / kg every 12 hours; newborn 1-4 weeks. . lives of 30-40 mg / kg intravenously every eight hours for adults for the prevention of postoperative infectious complications introduced into / in a dose of 2 grams per 30 minutes prior to surgery; if indicated, in the first postoperative day 2 g every 6 hours. During the cesarean section 2 g Anaerotsefa ® is administered in / in immediately after cord clamping.Babies and children up to 12 years, Anaerotsef ® is administered in / in 30 minutes before the operation at a dose of 30-40 mg / kg. As indicated, in the first postoperative day the drug further administered 30-40 mg / kg every 6-8 hours (neonatal – 08.12 h).

 

Preparation of solutions, methods of administration Intramuscular For the / m of sterile powder Anaerotsefa ® dissolved in sterile water for injection, 0.5% or 1% lidocaine hydrochloride solution. The following minimum amount of solvent is added directly into a vial of dry powder of the antibiotic:

The vial containing 0.5 g Anaerotsefa ® 1 ml
The vial containing 1.0 g Anaerotsefa ® 2 ml

The resulting solution is injected deep intramuscularly in the areas of the body with pronounced muscular layer (the upper-outer quadrant of the buttock or the lateral surface of the thigh). It is recommended to conduct a test on the aspiration to avoid unwanted introduction of the solution into a blood vessel. Intravenous For in / bolus Anaerotsef ® dissolved in sterile water for injection. The following minimum amount of solvent is added directly into a vial of dry powder of the antibiotic:

The vial containing 0.5 g Anaerotsefa ® 5 ml
The vial containing 1.0 g Anaerotsefa ® 10 ml

The resulting solution was introduced into / in slowly, over 3-5 minutes; . can be introduced through a special node or port injection system for the on / in infusion if the patient receives parenteral fluid
For in / drip in a 0.5 g Anaerotsefa ® is dissolved in 5 ml, 1 g – 10 ml of sterile water for injection. The resulting solution was added to the vial containing 50-400 ml compatible infusion fluid: 0.9% NaCl solution, 5% dextrose solution, an aqueous solution containing 5% dextrose and 0.9% sodium chloride; intravenously administered using intravenous infusion system.
Do not use solutions containing preservatives (e.g. benzyl alcohol in bacteriostatic water for injection) for the preparation of solutions Anaerotsefa ® , used in infants.

Side effects: Allergic reactions : rash, exfoliative dermatitis, toxic epidermal necrolysis (Lyell’s syndrome), eosinophilia, fever, shortness of breath, rarely – anaphylactic reactions, angioedema. Local reactions : thrombophlebitis after intravenous injection; pain, induration in places in / m injections From the urinary system : increased serum creatinine, interstitial nephritis, renal failure. From the digestive system : nausea, vomiting, dry mouth, decreased appetite, diarrhea, pseudomembranous enterocolitis. On the part of the system blood: leukopenia, granulocytopenia, neutropenia, anemia, thrombocytopenia, bone marrow suppression, hemolytic anemia. cardio-vascular system: arterial hypotension. Laboratory findings: patients with azotemia possible false positive Coombs’ test, increased activity of “liver” enzymes. Other: worsening trends myastenia gravis.

Interaction with other medicinal products
In an application with aminoglycosides observed synergy of antimicrobial activity, mainly in respect of the Enterobacteriaceae .
Solutions Anaerotsefa ® is compatible with 0.9% sodium chloride solution, 5% dextrose; solution for infusion containing 0.45% NaCl and 5% dextrose; solution for infusion containing 0.9% sodium chloride and 5% dextrose; 5% dextrose in Lactated Ringer’s solution, lactated Ringer’s solution, 2.5%, 5% and 10% solution of mannitol, M / 6 sodium lactate solution.
It should not be mixed in the same syringe or a fluid medium solutions Anaerotsefa ® and aminoglycosides .
Drugs that block tubular secretion, increase in blood drug concentration and duration of action.
The concurrent use of other cephalosporins, aminoglycosides and increases the risk of nephrotoxicity.

Cautions
Anaerotsef ® is used as a single antibiotic (monotherapy) for the treatment of mixed aerobic-anaerobic infections a wide variety of locations, including those caused by bacterial strains that are resistant to penicillins, other cephalosporins, lincosamides and aminoglycosides.
Patients who had a history of allergic reactions to penicillins, may be sensitive to cephalosporin antibiotics.
should be used solvent without preservatives for the treatment of newborns. The use of high doses in children is accompanied by an increase in the frequency of eosinophilia and increased activity asparaginamino-transferases.
Anaerotsef ® is not recommended for the treatment of bacterial meningitis.
When using the method of Jaffe may falsely inflated the concentration of creatinine in serum, it is not recommended to take blood samples for determination of creatinine for 2 anadrol reviews hours after administration.

anadrol 50

Pharmacodynamics anadrol 50 is highly selective nonsteroidal aromatase inhibitor – an enzyme, whereby in postmenopausal women androstenedione in peripheral tissues is converted into estrone and then to estradiol. Reduced levels of circulating estradiol in breast cancer patients has a therapeutic effect. In postmenopausal women, anadrol 50 at a daily dose of 1 mg estradiol levels causes a decrease of 80%.
anadrol 50 has no progestogenic, androgenic and estrogenic activity. anadrol 50 at daily doses up to 10 mg had no effect on the secretion of aldosterone and cortisol, therefore the application is not required substitution anadrol 50 corticosteroids.

Pharmacokinetics
Absorption anadrol 50 prompt, the maximum plasma concentration is reached within 2 hours after ingestion (fasting). Food slightly decreases the rate of absorption, but not its extent and does not result in a clinically significant effect on the equilibrium concentration of drug in blood plasma after a single reception daily dose of anadrol 50. After 7-day dosing is achieved approximately 90 – 95% of the equilibrium concentration of anadrol 50 in plasma. Recorded anadrol 50 pharmacokinetic parameters depending on the time or dose not. The pharmacokinetics of anadrol 50 is independent of age in postmenopausal women. Contact with blood plasma proteins -. 40%
Anastrazole displayed slowly, half-life from plasma is 40-50 hours. Extensively metabolized in postmenopausal women. Less than 10% of the dose is excreted in the urine unchanged within 72 hours after ingestion. Metabolism performed during N-dealkylation, hydroxylation and glucuronidation. Metabolites are excreted mainly by the kidneys. Triazole major metabolite determined in blood plasma does not possess pharmacological activity.
Total clearance after oral administration of anadrol 50 in cirrhosis or renal dysfunction is not changed.

Indications

• Adjuvant treatment of early breast cancer, hormone receptor-positive postmenopausal women, including after adjuvant tamoxifen therapy for 2-3 years.
• First-line treatment of locally advanced or metastatic breast cancer with positive or unknown hormone receptor in postmenopausal women.
• The second-line treatment of advanced breast cancer progressing after treatment with tamoxifen in postmenopausal women.

Contraindications

– Hypersensitivity to anadrol 50 or other components of the preparation.
– In premenopausal women.
– Severe hepatic impairment (safety and efficacy not established).
– Concomitant therapy with tamoxifen.
– Pregnancy and lactation.
– Children’s age (safety and efficacy in children not installed)

Precautions : lactase deficiency, galactose intolerance, glucose-galactose malabsorption (lactose contained in the dosage form of the drug).

Dosing and Administration

Inside. Swallow the tablet whole with water. It is recommended to take the drug at the same time, regardless of the meal. Adults, including the elderly : 1 mg orally 1 time a day for a long time. As an adjuvant therapy, the recommended duration of treatment – 5 years. If signs of progression of the disease taking the drug should be discontinued. Renal function : a dose adjustment in patients with impaired renal function is not required. Violations of the liver : a dose adjustment in patients with mild to moderate impaired liver function is not required.

 

Side effect

The frequency of adverse reactions listed below was determined according to the following criteria: very often (at least 1.10); frequently (more than 1/100 of less than 1/10.); sometimes (more than 1/1000 of less than 1/100.); rarely (over 1/10000, 1/1000 less); very rare (less than 1/10000), including isolated reports. On the part of the vessels: very often – “tides” of blood to the face. On the part of the musculoskeletal and connective tissue disorders: very often – arthralgia / joint stiffness, arthritis; often – bone pain, myalgia; infrequently – trigterny finger. From the genital and breast cancer: often – dryness of the vaginal mucosa, vaginal bleeding (mainly in the first weeks after the cancellation or change of previous hormonal therapy anadrol 50). Skin and subcutaneous tissue disorders: very common – skin rash; often – thinning hair, alopecia, allergic reactions; rarely – urticaria; rarely – erythema multiforme, anaphylactoid reactions, cutaneous vasculitis (including isolated cases of purpura (Henoch-Henoch syndrome)), very rarely – Stevens-Johnson Syndrome, angioedema. On the part of the gastrointestinal tract: often – nausea; often – diarrhea, vomiting. Liver and biliary tract: often – increasing the activity of alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase; rarely – increased activity of gamma glutamintransferazy and bilirubin, hepatitis. From the nervous system: very often – headache; often – drowsiness, carpal tunnel syndrome (mainly seen in patients with risk factors for the patients of the disease), sensory disturbances (including paraesthesia, loss or distortion of taste sensation). On the part of metabolism and nutrition: often – anorexia, hypercholesterolemia; seldom – hypercalcemia (with / without increasing paratgormoia concentration). The drug can cause a reduction in bone mineral density due to lower concentrations of circulating estradiol, thereby increasing the risk of osteoporosis and bone fractures. General disorders: very often – asthenia, mild or moderate in severity. Adverse events reported in clinical trials are not associated with taking anadrol 50: anemia, constipation, indigestion, back pain, abdominal pain, increased blood pressure, weight gain, depression, insomnia, dizziness, anxiety, paresthesia.

Overdose

We describe the individual clinical cases of accidental overdose. A single dose of anadrol 50, which could lead to the symptoms, life-threatening, has not been established.
The specific antidote does not exist; in the case of overdose, treatment should be symptomatic. It is possible to induce vomiting if the patient is conscious. Dialysis can be performed. Recommended general supportive therapy, monitoring patients and control the function of vital organs and systems.

Interaction with other drugs

Clinically significant drug interactions when taking anadrol 50 in conjunction with other commonly prescribed drugs available.
At the moment, there are no data on the use of anadrol 50 in combination with other anticancer drugs.
Studies on drug interactions with phenazone and cimetidine indicate that the combined use of anadrol 50 with other drugs is unlikely to result in clinically significant drug interactions mediated by cytochrome P450.
Preparations containing estrogens reduce the pharmacological effect of anadrol 50, and therefore, they should not be administered concurrently with anadrol 50.
it should appoint tamoxifen concurrently with anadrol 50 because it can weaken the pharmacological action of the latter.

special instructions

The safety and efficacy of anadrol 50 in children has not been established.
Women with retseptorootritsatelnoy tumor estrogen efficacy of anadrol 50 has not been demonstrated, except in cases where there was a previous positive clinical response to tamoxifen.
In case of doubt in the hormonal status of the patient menopause must be confirmed by the definition of sex hormones serum.
There are no data on the use of anadrol 50 in patients with severe liver dysfunction.
In the case of persistent uterine bleeding in patients receiving anadrol 50 need advice and supervision of the gynecologist.
preparations containing estrogens should not be administered concurrently with anadrol 50, as these drugs will reverse the its pharmacological effect.
by reducing the level of circulating estradiol, anadrol 50 can cause a reduction in bone mineral density
in patients with osteoporosis or have risk of developing osteoporosis, bone mineral density should be assessed by densitometry (eg, DEXA scan) at the beginning of treatment and in the dynamics. If necessary, must be initiated by the treatment or prevention of osteoporosis under the close supervision of a physician.
No data on the concomitant use of anadrol 50 and preparations analog of luteinizing hormone-releasing hormone (LHRH).
It is unknown whether anadrol 50 results improves treatment when used in conjunction with chemotherapy.
The efficacy and safety at the same time use of tamoxifen, regardless of hormone receptor status comparable with those using a tamoxifen.
Some side effects of anadrol 50, such as fatigue and drowsiness, may adversely affect the ability to perform potentially hazardous activities that require high concentration and speed of psychomotor reactions. In this connection, it is recommended with the appearance of these symptoms to be careful in the management of vehicles and mechanisms.

anadrol

It has analgesic, antipyretic and weak anti-inflammatory activity, the mechanism of which is associated with inhibition of prostaglandin synthesis. It is pyrazolone derivative.  When intravenous: onset of action – within 5-10 minutes, the maximum effect – after 5-30 minutes duration – up to 2 hours. It is metabolized in the liver, small concentration constant anadrol detected in plasma, excreted by the kidneys. At therapeutic doses, it penetrates into breast milk.

Pain (mild to moderate severity): including: neuralgia, myalgia, arthralgia, biliary colic, intestinal colic, renal colic, injury, burns, decompression sickness, shingles, orchitis, sciatica, myositis, postoperative pain, headache, toothache, tuberculosis. Feverish syndrome (infectious and inflammatory diseases, insect bites -. Mosquitoes, bees, horseflies, etc., post-transfusion complications).
The drug is intended for symptomatic therapy reduce pain and inflammation at the time of use, does not affect the progression of the disease.

Contraindications
: Hypersensitivity to pyrazolone derivative (phenylbutazone, tribuzon), a tendency to bronchospasm.
Severe hepatic dysfunction and / or kidney disease, deficiency of glucose-6-phosphate dehydrogenase, blood diseases, blood oppression (agranulopitoz, cytostatic or infectious neutropenia), and – anemia and leukopenia. Bronchial obstruction, rhinitis, urticaria provoked by taking aspirin or other nonsteroidal anti-inflammatory drugs (including a history..), Active liver disease, condition after coronary artery bypass surgery; confirmed hyperkalemia, erosive and ulcerative changes in gastric mucosa and 12 duodenal ulcer, active gastrointestinal bleeding, inflammatory bowel disease. Infants up to 3 months.
Use during pregnancy and lactation.
Do not use during pregnancy (especially during the first 3 months and 6 weeks) and lactation.

Precautions
Coronary heart disease, chronic heart failure, cerebrovascular disease, dyslipidemia / hyperlipidemia, diabetes mellitus, peripheral arterial disease, smoking, creatinine clearance less than 60 mL / min. a history of the development of ulcerative lesions of the gastrointestinal tract, the presence of H. pylori infection, old age, long-term use of nonsteroidal anti-inflammatory drugs, severe somatic diseases, concomitant use of oral corticosteroids (in Vol. h. prednisone), anticoagulants (in Vol. h. warfarin), antiplatelet agents (in T. Ch acetylsalicylic acid, clopidogrel), selective serotonin reuptake inhibitors (as Charles T. citalopram, fluoxetine, paroksetip, sertraline).
Special care is required when assigning patients with systolic blood pressure below 100 mm Hg . Art. or circulatory instability (eg in myocardial infarction, multiple trauma commencing shock), with indications of a history of renal diseases (pyelonephritis, glomerulonephritis) and long-term history of alcohol.

Dosing and dose
preparation administered in / (in severe pain) or / m at 1 – 2 ml 250 mg / ml or 500 mg / ml of solution 2-3 times a day, but no more than 2 grams per day.
Babies administered of 0.1 – 0.2 ml 500 mg / ml or 0.2 -. 0.4 ml of 250 mg / ml per 10 kg body weight 2-3 times a day
for children up to 1 year of drug administered only V / m, the rate of no more than 3 days.

Side effects:
At therapeutic doses, the drug was well tolerated. In applying the drug in individual patients may experience side effects: allergic reactions (skin rash, angioedema, rare anaphylactic shock, Stevens-Johnson syndrome and Lyell, bronchospasm); long-term use can cause agranulocytosis, leukopenia, thrombocytopenia, hypotension, interstitial nephritis. Impaired renal function, oliguria, anuria, proteinuria, urine staining in red.
When the propensity to bronchospasm may provoke an attack. When i / m administration may infiltrate at the injection site.

Overdosing Symptoms: nausea, vomiting, gastralgia, oliguria, hypothermia, lowering blood pressure, tachycardia, shortness of breath, tinnitus, drowsiness, delirium, impaired consciousness, acute agranulocytosis, hemorrhagic syndrome, acute renal and / or hepatic impairment, convulsions, paralysis, respiratory . muscle Treatment: induction vomiting, chrezzondovoe gastric lavage, saline laxatives, activated carbon; carrying out forced diuresis, hemodialysis, in the development of convulsions – in / diazepam and barbiturates fast.

Interaction with other medicinal products
due to the high probability of pharmaceutical incompatibility can not be mixed with other drugs in the same syringe. It enhances the effects of ethanol; simultaneous application of chlorpromazine and other phenothiazine derivatives can lead to severe hyperthermia.
Radiopaque substances, colloidal blood substitutes and penicillin should not be used during treatment anadrol. When concomitant administration of cyclosporine snizhaetdya concentration of the latter in the blood. anadrol, displacing connection with protein oral hypoglycemic drugs, indirect anticoagulants, steroids and indomethacin, increases their activity. Phenylbutazone, barbiturates and other gepatoinduktory while appointing reduce the effectiveness anadrol. Co-administration with other non-narcotic analgesics, tricyclic antidepressants, contraceptive hormonal agents and allopurinol may lead to increased toxicity, Sedatives and tranquilizers increase the analgesic effect anadrol. Tiamazol sarkolizin and increase the risk of leukopenia. The effect of increasing codeine, histamine H2-blockers and propranolol (slow inactivation). Myelotoxic drugs increase the expression gematotoksichnosti anadrol.

Specific guidance
in the treatment of children under 5 years and patients receiving cytotoxic agents, receiving dipyrone should be done only under medical supervision. In patients with atopic asthma and hay fever have an increased risk of developing hypersensitivity reactions. With long-term (more than a week) the application necessary to monitor patterns of peripheral blood and functional state of the liver. In patients receiving dipyrone may develop agranulocytosis, and therefore, the detection of unmotivated rise in temperature, chills, sore throat, difficulty swallowing, stomatitis, as well as the development of vaginitis or proctitis require immediate removal of the drug. Intolerance occurs rarely, but the shock of a threat after the on / in the preparation is relatively higher than after oral administration of the drug. It is not permissible to use to relieve acute pain in the abdomen (to determine the cause). When i / m administration is necessary to use a long needle.

Product form
The solution for in / in / m of 250 mg / ml or 500 mg / ml (ampoules) – 1 or 2 ml. 10 ampoules with a knife or lancet ampulnam and instructions for use in a pile of cardboard.
On 5 vials in blisters. On 2 blisters with a knife or lancet ampulnam and instructions for use in a pile of cardboard. When packing vials with a point or ring fault knife scarifier ampoule or do not invest.